Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours), drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Whether adjuvant chemotherapy helps type I PPB; the registry is comparing outcomes with and without it.
Type III and recurrent PPB have poor outcomes and no targeted therapy; DICER1-dependent biology (miRNA processing) has not yet yielded a drug.
Uptake of germline testing and surveillance across families, and the psychological burden of surveillance in carriers.
Diagnostic delay for childhood airway tumours misdiagnosed as asthma.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Surveillance per international consensus: chest imaging in infancy and early childhood, abdominal ultrasound, thyroid ultrasound, and awareness of ovarian and other syndrome tumours.
A milestone in how this cancer is treated.
Neoadjuvant or adjuvant multi-agent chemotherapy (ifosfamide, vincristine, dactinomycin, doxorubicin) with complete resection; radiotherapy for unresectable residual disease.
Messinger and colleagues (Cancer 2015) report outcomes by type.
Hill and colleagues (Science) identify the first microRNA-processing gene tumour syndrome.